Non-Surgical Skin Cancer Treatment | SRT-100™ Sensus Healthcare

A sensitive approach to non-melanoma skin cancer

Sensus Healthcare is dedicated to improving the lives of men and women who suffer from skin cancer. We believe every patient deserves a choice. It’s the reason we offer a painless, safe and highly effective non-surgical skin cancer treatment that is an alternative to surgery—Superficial Radiation Therapy using the SRT-100™.

Today, nearly five million people in the United States are treated for skin cancer, with four million new cases of basal and squamous cell (non-melanoma) skin cancer diagnosed each year. Treatment often involves invasive incisions that damage healthy tissue, painful healing, lengthy recovery and unsightly scarring that takes an emotional toll on patients. Sensus Healthcare is changing all that.

QUICK CANCER FACTS

Each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate, lung and colon.
Treatment of non-melanoma skin cancers increased by nearly 77 percent between 1992 and 2006.
Each year in the US, nearly 5 million people are treated for skin cancer. In 2006, in the most recent study available, 3.5 million cases were diagnosed in 2.2 million people.
Over the past three decades, more people have had skin cancer than all other cancers combined.
One in five Americans will develop skin cancer in the course of a lifetime.
13 million white non-Hispanics living in the US at the beginning of 2007 had at least one nonmelanoma skin cancer, typically diagnosed as basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).
Between 40 and 50 percent of Americans who live to age 65 will have either basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) at least once.
Basal cell carcinoma is the most common form of skin cancer; an estimated 2.8 million are diagnosed annually in the US. BCCs are rarely fatal, but can be highly disfiguring if allowed to grow.
Squamous cell carcinoma is the second most common form of skin cancer. An estimated 700,000 cases of SCC are diagnosed each year in the US.
The incidence of squamous cell carcinoma has been rising, with increases up to 200 percent over the past three decades in the US.
Organ transplant patients are up to 250 times more likely than the general public to develop squamous cell carcinoma (SCC).
About two percent of squamous cell carcinoma patients – between 3,900 and 8,800 people – died from the disease in the US in 2012.
As many as three thousand deaths from advanced basal cell carcinoma occur annually in the US.
Actinic keratosis is the most common precancer; it affects more than 58 million Americans.
Approximately 65 percent of all squamous cell carcinomas and 36 percent of all basal cell carcinomas arise in lesions that previously were diagnosed as actinic keratoses.
About 90 percent of non-melanoma skin cancers are associated with exposure to ultraviolet (UV) radiation from the sun.

A non-surgical skin cancer treatment that makes sense

Leveraging clinically-proven technology that has been used for more than 50 years, the innovative SRT-100™ delivers a precise, calibrated dose of Superficial Radiation Therapy that only goes skin deep. This low-dose of radiation safely destroys non-melanoma skin cancer cells. Performed right in the doctor’s office, Superficial Radiation Therapy with the SRT-100™ delivers optimum results without the negative side effects of invasive treatments. It is ideal for patients with existing medical conditions that make surgery a serious health risk.